Clinical Trial

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Name: CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms — clinical trial record (NCT07519187)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-10

Trial Details

NCT Number	NCT07519187
Lead Sponsor	The General Hospital of Western Theater Command
Conditions	Relapsed or Refractory Plasma Cell Neoplasms
Enrollment	20 participants
Start Date	2026-04-23
Primary Completion	2027-04-01 (estimated)
Study Completion	2028-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-09